Switch studies in virologically suppressed patients

Switch to ATV/r monotherapy
Swedish study
Original article : J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):417-22 – O Karlström
Last update : Epub 2007 Nov 13

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Failure of ATV/r as maintenance monotherapy

Design :

Primary endpoint :

  • Absence of virologic failure by W72 (2 consecutive HIV-1 RNA > 20 c/mL)

 

  • 15 patients enrolled
    • Prior ARV therapy
    • Median CD4 cell count/mm3: at inclusion = 440 ; nadir = 200
    • Median HIV-1 RNA before initiation of ARV therapy: 5.1 log10 c/mL
  • 5 virologic failures -> termination of the study
  • No PI resistance in samples from patients with virologic failure

 

Back to Table of Contents

     
     
     
Copyright AEI 2020 | Links | Contact | Editorial Office | Faculty and Disclosure | Terms of use aei